

Who we are

Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems dedicated to making genomics useful for all. Innovating at the intersection of technology, biology, and health, we are reimagining what's possible for human health and the health of our planet, including how diseases—from cancer to COVID-19—are discovered, detected, diagnosed, and treated. We provide sequencing innovations that are enabling researchers and clinicians to usher in the future of personalized medicine.




Fast facts



Founded in
1998



Number of employees
~9,250



Annual revenue (2023)¹
\$4.50B USD



Cumulative sequencing installed base
> 25,000

Headquarters

San Diego, California, USA

Countries served

> 160

Chief Executive Officer

Jacob Thaysen

Sequencing systems

Next-generation sequencing (NGS) is revolutionizing research, enabling experiments that weren't possible before. Illumina offers a range of innovative NGS platforms that deliver exceptional data quality and accuracy, at a massive scale.



**NovaSeq™
X/X Plus**

**NovaSeq
6000/6000Dx***

**NextSeq™
1000/2000**

**NextSeq
550/550Dx***

**MiSeq™ and
MiSeqDx***

MiniSeq™ iSeq™ 100

Production-scale systems

Benchtop systems

Applications

- Oncology
- Genetic disease
- Infectious disease
- Multiomics
- Drug discovery
- Microbial genomics
- Reproductive health
- Molecular and cell biology
- Agriculture
- Conservation and sustainability

Customers

- Clinics
- Hospitals
- Research labs
- Health care systems
- Academic institutions
- Government agencies
- Pharmaceutical companies

For Research Use Only. Not for use in diagnostic procedures.

*For *In Vitro* Diagnostic Use. Not available in all regions and countries.

Making breakthroughs possible

As a genomics pioneer, we have proven through focused and continued innovation how unlocking the power of the genome can exponentially improve the human condition and the world around us.

Our ability to drive patient outcomes has made us a trusted partner in health care. Today, we're providing tools that enable the next generation of researchers and clinicians to usher in the future of personalized medicine.

Cost of sequencing per human whole genome



Since 2001, the cost of DNA sequencing has dropped more than 100,000x from \$100 million USD per human genome to \$200 USD list price.

Where we operate

United States

San Diego (headquarters)
Foster City
Hayward
Baltimore
Madison

Brazil

São Paulo

United Kingdom

Cambridge

Belgium

Mechelen

France

Évry
Rennes

Germany

Berlin

Italy

Milan

Israel

Tel Aviv

Netherlands

Eindhoven

Turkey

Istanbul

United Arab Emirates

Dubai

India

Bengaluru

China

Beijing
Shanghai
Guangzhou
Hangzhou
Taipei City

Japan

Tokyo
Osaka

Singapore

Australia

Melbourne
Sydney

South Korea

Seoul



Corporate social responsibility

As a global corporate citizen, Illumina is committed to deepening our impact on human health by serving as a champion for patients, the community, and our planet.

Facilities

- Green building design
- Reduce CO₂ emissions
- Increase renewable energy
- Reduce water footprint
- Reduce waste to landfill
- Science Based Targets initiative (SBTi)-certified for 2050 net-zero carbon targets

Product

- Design for environment
- Package and dry ice reduction

Supply chain

- Supplier commitments
- Supplier diversity

2030 Targets

90%

Diversion of landfill waste at all main campuses⁴

75%

Reduction in packaging

20%

Diverse supplier spend

Our recognition



1. 2023 Annual Revenue provided in February 2024.

2. Wetterstrand KA. The Cost of Sequencing a Human Genome. National Human Genome Research Institute. <https://www.genome.gov/about-genomics/fact-sheets/Sequencing-Human-Genome-cost>. Updated November 1, 2021. Accessed November 17, 2022.

3. \$200 USD genome on NovaSeq[™] X Series is delivered at list price on 25B flow cell. Data on file.

4. Main campus locations currently include San Diego, Foster City, Hayward, UK Illumina Centre, Netherlands, and Singapore Woodlands.